Gritstone Bio Profit Margin 2017-2022 | GRTS

Current and historical gross margin, operating margin and net profit margin for Gritstone Bio (GRTS) over the last 10 years. Profit margin can be defined as the percentage of revenue that a company retains as income after the deduction of expenses. Gritstone Bio net profit margin as of June 30, 2022 is -634.23%.
Gritstone Bio Annual Profit Margins
Gritstone Bio Quarterly Profit Margins
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.327B $0.048B
Gritstone Oncology is developing tumor-specific cancer immunotherapies to fight multiple cancer types. The company has built its tumor-specific immunotherapy approach on two key pillars - first, a proprietary machine learning-based platform, Gritstone EDGE(TM), which provides a powerful ability to predict from a routine tumor biopsy the tumor-specific neoantigens, or TSNA, that are presented on a patient?s tumor cells; and second, the ability to develop and manufacture potent immunotherapies utilizing patients? TSNA to drive the patient?s immune system to attack and destroy tumors.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $158.329B 9.60
GSK (GSK) United Kingdom $69.653B 8.36
Bio-Rad Laboratories (BIO.B) United States $15.412B 34.05
QIAGEN (QGEN) Netherlands $10.761B 18.02
Biohaven Pharmaceutical Holding (BHVN) United States $10.584B 0.00
Ginkgo Bioworks Holdings (DNA) United States $5.801B 0.00
Arcus Biosciences (RCUS) United States $1.834B 35.79
Myovant Sciences (MYOV) United Kingdom $1.749B 0.00
Emergent Biosolutions (EBS) United States $1.421B 8.24
Zymeworks (ZYME) Canada $0.371B 0.00
Enzo Biochem (ENZ) United States $0.126B 0.00
Gelesis Holdings (GLS) United States $0.095B 0.00
SQZ Biotechnologies (SQZ) United States $0.093B 0.00
Ambrx Biopharma (AMAM) United States $0.080B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.000B 0.00